<prompt> Cetuximab an EGFR antagonist can be used in:Palliation in head and neck cancerAnal canal carcinomaGastric carcinomaLung carcinoma  <response>: CETUXIMAB: It is a chimeric monoclonal antibody directed to the extracellular domain of the EGF receptor. USES: Colorectal Cancer Indications Indicated for treatment of KRAS mutation-negative wild-type, epidermal growth factor receptor EGFR-expressing, metastatic colorectal cancer as determine by FDA-approved tests eg, therascreen KRAS RGQ PCR Kit for this use Determine EGFR-expression status using FDA-approved tests prior to initiating treatment; also confirm absence of a Ras mutation prior to initiation of treatment 1 In combination with FOLFIRI irinotecan, 5-fluorouracil, leucovorin for first-line treatment, 2 In combination with irinotecan in patients who are refractory to irinotecan-based chemotherapy, and 3 As a single agent in patients who have failed oxaliplatin- and irinotecan-based chemotherapy or who are intolerant to irinotecan Dosage Dosage is for either monotherapy or in combination Loading Initial dose: 400 mgm2 IV infused over 2 hr Maintenance: 250 mgm2 IV infusion over 60 min qWeek until disease progression or unacceptable toxicity Complete cetuximab administration 1 hr prior to FOLFIRI Not to exceed infusion rate of 10 mgmin Limiation of use Not indicated for the treatment of patients with colorectal cancer that harbor somatic mutations in exon 2 codons 12 and 13, exon 3 codons 59 and 61, and exon 4 codons 117 and 146 of either K-Ras or N-Ras referred to as Ras or when he results of the Ras mutation tests are unknown Head Neck Cancer Indications Indicated for initial treatment of locally or regionally advanced squamous cell carcinoma of headneck with radiation therapy Monotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck progressing after platinum-based therapy Combined with platinum-based therapy with 5-FU for metastatic head and neck cancer Initial dose: 400 mgsm2 IV infused over 2 hr Subsequent doses: 250 mgm2week; infuse over 60 minutes not to exceed 10 mgmin With radiation: Initiate 1 week prior to beginning radiation therapy, continue qWeek x 6-7 weeks With platinum-based therapy with 5-FU: Initiate on the day beginning chemotherapy; complete cetuximab infusion 1 hr prior to administering platinum-based therapy with 5-FU Monotherapy or with chemotherapy: Administer qWeek until disease progression or unacceptable toxicity REFERENCE: 